Psilocybin

Last updated 2026-10-03 · updated daily by an automated research job · run #2.

The verdict

The current state of the art, as of 2026-10-03 (confidence secondary):

Psilocybin remains in late-stage clinical development for treatment-resistant depression, with positive Phase 3 results from Compass Pathways and an FDA review underway. Preliminary, often open-label, evidence supports potential in other psychiatric (OCD, PTSD, bipolar II) and medical (post-treatment Lyme, chemo neuropathy prevention) conditions. The field's central methodological challenge—blinding—remains unsolved.

Contenders:

• Treatment-resistant depression — Most mature indication with two positive Phase 3 trials and an FDA filing in progress.
• Major depressive disorder — Usona Phase 3 completed enrollment; holds FDA priority voucher; results pending.
• Chemo nerve damage — Strong preclinical data in Science; Phase 2 trial starting Nov 2026 represents a major expansion into a non-psychiatric medical indication.

What this is, and how it works

This page is generated, not written. A scheduled job runs daily on a machine in a homelab. Each run it:

1. Searches the open web for both the products already tracked here and for category-level terms designed to turn up ones we've never heard of.
2. Feeds those results to a language model along with everything already on this page, and asks it what is genuinely new. Finding nothing is an acceptable answer, and most runs should find little.
3. Writes the result into a versioned JSON dataset (data/live-research/psilocybin.json) and commits it. This page is re-rendered from that file.

So: a machine wrote the prose here. Every changelog entry carries at least one source link, and every item and entry carries a confidence label:

• primary-source — vendor documentation, a published paper, or a regulator.
• secondary — reputable press.
• vendor-claim — marketing or an unreplicated vendor statement.
• unverified — a single low-quality source, usually auto-discovered.

Any label weaker than primary-source is printed beside the finding, so an unflagged row is a primary source. A tracker that hides its own uncertainty is worse than no tracker.

What this is not. Not medical advice. Not a review site — nothing here has been tested in our hands. No affiliate relationships, no sponsored placements, nothing bought. Vendor claims are attributed to the vendor rather than restated as findings. Where a price, a date, or a regulatory status is unknown, it is left blank instead of guessed.

What's new

26 developments in the last 30 days, newest first.

The last 30 days

The last month saw a major positive trial readout and a significant negative one. The NHS-funded PsiDeR trial (n=60) for treatment-resistant depression (TRD) showed a 50% response rate at week 6 with a single 25 mg dose, far exceeding placebo. Conversely, the German EPIsoDE Phase 2b trial (n=144) missed its primary endpoint, though secondary measures favored psilocybin. Compass Pathways announced vendor-claim data showing a third dose in an open-label extension extended benefits to one year, and it targets a potential 2027 U.S. launch for COMP360. A new case report also highlighted risk, detailing worsened depression and anxiety in a patient with cyclothymia after psilocybin use.

Outside depression, early but promising open-label data was published for bipolar II depression and PTSD. A pilot in bipolar II (n=14) showed large MADRS score reductions but also transient suicidal ideation or hypomania in 3 of 14 participants. A study in veterans with severe, treatment-resistant PTSD (n=12) found 9 of 12 in remission at one month. For OCD, a preclinical study in mice found psilocybin restored social behavior, but this is not human evidence.

On the mechanism front, a negative finding stands out: a rat study found chronic psilocin microdosing produced limited behavioral effects and did not enhance neurogenesis. Another study identified a subperceptual dose threshold (<2.5 mg) in healthy adults. A pilot RCT (vendor-claim) reported psilocybin reduced egocentric bias in alcohol use disorder, and a new protocol was published to test psilocybin combined with apomorphine for coma recovery.

In the real world, Oregon's program published its first outcome cohort (n=346, no control), with over 90% reporting benefit at one month and low rates of serious harm, though sessions remain expensive. State regulators rescinded a plan to double licensing fees after pushback. For a reader, the field remains defined by its blinding problem and variable results. The most concrete near-term event is the FDA's Q4 2026 decision on Compass's NDA for TRD.

Written 2026-10-03 from the changelog below, not from a fresh search.

Drawn from:

• Protocol: Open-label dose-escalation study of apomorphine + psilocybin for recovery from coma in ICU. — 2026-10-03, confidence primary-source
• Pilot RCT: Psilocybin (25 mg) reduced egocentric bias in individuals with alcohol use disorder. — 2026-10-03, confidence primary-source
• Cybin Inc. changes legal name to Helus Pharma. — 2026-10-03, confidence secondary
• Preclinical: Chronic psilocin microdosing produced limited behavioral effects, no enhanced neurogenesis in rats. — 2026-10-03, confidence primary-source
• Compass Pathways' 52-week open-label data from Phase 3 COMP005 shows additional benefit from another COMP360 dose, extending durability out to 1 year. — 2026-10-03, confidence vendor-claim
• Compass Pathways targets potential COMP360 launch in 2027 as FDA review advances. — 2026-10-03, confidence secondary
• Case report: Psilocybin worsened depression and anxiety in a patient with cyclothymia. — 2026-10-03, confidence primary-source
• RCT, n=37: Single moderate dose of psilocybin (0.215 mg/kg) significantly reduced depressive symptoms and improved self-concept in MDD. — 2026-10-03, confidence vendor-claim
• Oregon Health Authority rescinds proposed psilocybin service license fee hikes. — 2026-10-03, confidence secondary
• Randomized, double-blind, placebo-controlled, single-ascending-dose study identifies a subperceptual dose of psilocybin (<2.5 mg) in healthy adults. — 2026-10-03, confidence primary-source
• Study finds psychedelics and anesthetics create mirror-image brain network patterns related to consciousness. — 2026-10-03, confidence secondary
• Preclinical study: Single psilocybin dose improves social behavior in OCD mouse model. — 2026-10-03, confidence secondary
• Review argues strongest studies on psilocybin microdosing show limited benefits. — 2026-10-03, confidence secondary
• Open-label, n=20: ~70% had little or no suicidal ideation 12 weeks after psilocybin with therapy. — 2026-10-02, confidence secondary
• Open-label, n=14: MADRS -12.7 after 10 mg (29% remission), -18.6 after 25 mg (n=9); 3 had transient suicidal ideation or hypomania. — 2026-10-02, confidence primary-source
• Mice: two preventive doses blocked cisplatin/paclitaxel nerve damage for 8 months without blunting chemo; non-hallucinogenic tabernanthalog worked as well. — 2026-10-02, confidence primary-source
• Cohort, n=346, no control: 91.5% reported benefit at 1 month; 1.2% needed medical attention (all first-timers); 2% called it harmful at 3 months. — 2026-10-02, confidence primary-source
• fMRI, n=62 healthy adults: brain networks blurred together but into different patterns by setting (rest, music, meditation, movie); more reorganisation predicted more next-day benefit. — 2026-10-02, confidence primary-source
• RCT vs placebo, n=60, one 25 mg dose: response 50% vs 3% at week 6; remission 40% vs 3% at week 3; MADRS -10.4 vs placebo. — 2026-10-02, confidence primary-source
• Open-label, n=12 veterans with severe treatment-resistant PTSD, 15 + 25 mg: clinician-rated PTSD score -27.5 at 1 month; 9 of 12 in remission. — 2026-10-02, confidence primary-source
• Placebo crossover, n=28: brain entropy rose within an hour, white-matter tracts denser a month later; insight mediated the gain in well-being. — 2026-10-02, confidence primary-source
• FDA grants National Priority Vouchers to Compass (COMP360, TRD) and Usona (MDD); review drops to 1-2 months after filing. — 2026-10-02, confidence primary-source
• RCT, n=144, 25 mg vs 5 mg vs active placebo: missed its primary endpoint (response at week 6); secondary measures favoured psilocybin, more after the second dose. — 2026-10-02, confidence primary-source
• Randomized, n=15, blinded vs lorazepam then up to 8 open high doses: 73% responders, 40% remission at 8 weeks; faded but substantial at 6 months. — 2026-10-02, confidence primary-source
• Two Phase 3 RCTs, >1,000 patients, 25 mg vs 1 mg: both met primary endpoint, MADRS -3.8 at week 6; two doses beat one; durable to 6 months. — 2026-10-02, confidence primary-source
• Open-label, n=20, two doses: symptom burden -40% and quality of life +13%, sustained to 6 months. — 2026-10-02, confidence primary-source

The last year

Over the last twelve months, the strongest signal is that psilocybin for treatment-resistant depression works, but the effect is modest and depends on multiple doses. Compass Pathways’ Phase 3 program, which serves as the field’s primary evidence, found a 3.8-point advantage on the MADRS scale over an active 1 mg control at six weeks—a clinically meaningful but not transformative difference. Critically, two doses consistently outperformed one, a finding reinforced by new 52-week data from Compass, which the company claims shows an additional benefit from a third dose. However, a German Phase 2b trial (EPIsoDE) with 144 patients missed its primary endpoint, underscoring that results are not uniform. The FDA review, now on a fast track with a National Priority Voucher, points to a potential 2027 launch, making this the first pharmaceutical-grade psilocybin product likely to reach the market.

Beyond depression, small open-label studies continue to generate promising, if preliminary, signals for other conditions. A UK NHS-funded RCT for TRD showed a strong response rate (50% vs 3% on placebo), and pilots in severe PTSD, OCD, bipolar II depression, and post-treatment Lyme disease all reported substantial symptom reductions. Yet the data is thin, and risks are becoming clearer. A case report detailed worsened depression and anxiety in a patient with cyclothymia, and in the bipolar II pilot, 3 of 14 participants experienced transient suicidal ideation or hypomania. These findings caution that underlying mood instability may be a significant risk factor, even in controlled settings.

The most useful negative findings concern microdosing and mechanism. A preclinical study in rats found chronic psilocin microdosing produced limited behavioral effects and no enhanced neurogenesis, while a review argued the strongest human studies on microdosing show limited benefits. On the mechanism front, a large imaging study provided evidence that the therapeutic “set and setting” physically reshapes brain network patterns, and another found that gains in well-being were mediated by increases in insight. A separate preclinical study showed a non-hallucinogenic analogue (tabernanthalog) matched psilocybin’s effect in preventing chemotherapy-induced nerve damage in mice, suggesting the therapeutic mechanism may be separable from the psychedelic experience—though this is early vendor-claim territory.

Real-world access in Oregon has produced its first outcome data from 346 participants, with over 90% reporting benefit at one month and serious harms rare. However, only about half of participants had moderate-to-severe depression at baseline, and sessions cost hundreds to thousands of dollars, framing this largely as a wellness service for those who can pay. The state’s program also faces funding challenges, leading to a rescinded proposal to double licensing fees.

In summary, the last year solidified psilocybin’s pathway to FDA approval for TRD with a modest effect size, expanded early signals into half a dozen other psychiatric and medical conditions, and delivered concrete warnings about risks in unstable mood disorders. It also provided mechanistic evidence that context is neurologically embedded in the treatment and that microdosing claims remain unsupported. For anyone allocating attention or money, the commercial launch track is now clear, but the evidence for broader use remains a patchwork of small, open-label studies.

Written 2026-10-03 from the changelog below, not from a fresh search.

The ones that mattered:

• 2026-10-03 — Protocol: Open-label dose-escalation study of apomorphine + psilocybin for recovery from coma in ICU. (study, primary-source)
• 2026-10-03 — Pilot RCT: Psilocybin (25 mg) reduced egocentric bias in individuals with alcohol use disorder. (study, primary-source)
• 2026-10-03 — Preclinical: Chronic psilocin microdosing produced limited behavioral effects, no enhanced neurogenesis in rats. (negative, primary-source)
• 2026-10-03 — Compass Pathways' 52-week open-label data from Phase 3 COMP005 shows additional benefit from another COMP360 dose, extending durability out to 1 year. (study, vendor-claim)
• 2026-10-03 — Compass Pathways targets potential COMP360 launch in 2027 as FDA review advances. (regulatory, secondary)
• 2026-10-03 — Case report: Psilocybin worsened depression and anxiety in a patient with cyclothymia. (negative, primary-source)
• 2026-10-03 — RCT, n=37: Single moderate dose of psilocybin (0.215 mg/kg) significantly reduced depressive symptoms and improved self-concept in MDD. (study, vendor-claim)
• 2026-10-03 — Oregon Health Authority rescinds proposed psilocybin service license fee hikes. (regulatory, secondary)

All time

Depression remains the most advanced area, with Compass Pathways’ synthetic psilocybin (COMP360) for treatment-resistant depression (TRD) now on a clear path to market. Its two positive Phase 3 trials (>1,000 patients) showed a -3.8 point MADRS advantage over a 1 mg control at week 6—a modest but statistically significant effect. The FDA granted it a National Priority Voucher and rolling NDA review, with submission completion targeted for Q4 2026 and a potential U.S. launch in the first half of 2027. New 52-week open-label data from Compass, a vendor claim, suggests an additional dose can extend durability out to a year. However, the field’s methodological cracks are visible: a German Phase 2b trial (EPIsoDE, n=144) missed its primary endpoint, and a 2026 JAMA Psychiatry meta-analysis concluded that the apparent large effects of psychedelics shrink toward ordinary antidepressant margins once patients know what they received. For major depressive disorder (MDD), Usona Institute holds a priority voucher and has completed Phase 3 enrollment, but there is no readout yet. A smaller vendor-claim RCT (n=37) reported a single moderate dose significantly reduced depressive symptoms and improved self-concept.

Outside depression, small open-label pilots continue to show promise but lack controlled validation. For OCD, a small randomized trial (n=15) using up to eight doses reported a 73% response rate at 8 weeks; a new preclinical study in mice found psilocybin restored social behavior, linked to prefrontal cortex activation. For PTSD, an open-label pilot in veterans with severe treatment-resistant illness (n=12) found 9 of 12 in remission at one month. For chronic suicidal ideation, an open-label trial at Sheppard Pratt (n=20) reported ~70% of participants had little or no ideation at 12 weeks, though details are unconfirmed. In bipolar II depression, an open-label dose-escalation pilot (n=14) showed large MADRS drops but also noted 3 of 14 participants experienced transient suicidal ideation or hypomania; a separate case report warned psilocybin worsened depression and anxiety in a patient with cyclothymia, highlighting risk in those with underlying mood instability.

The most compelling new medical indication is chemotherapy-induced neuropathy. A preclinical study found two preventive psilocybin doses blocked nerve damage from cisplatin/paclitaxel in mice for eight months without blunting chemotherapy efficacy; a non-hallucinogenic analogue (tabernanthalog) worked equally well. A Phase 2 trial (NeuroGuard, n=83) is slated to start in November 2026. For post-treatment Lyme disease, an open-label Johns Hopkins pilot (n=20) found symptom burden down ~40% with benefits sustained to six months.

Real-world access via Oregon’s licensed services is now a fact, with the first outcome cohort (n=346, no control) showing 91.5% self-reported benefit at one month and low rates of serious harm (1.2% needed medical attention). Sessions cost hundreds to thousands of dollars. The Oregon Health Authority recently rescinded a proposal to double licensing fees after pushback, though the program faces funding shortfalls.

Mechanistic research is advancing. The largest psilocybin brain-imaging study to date (n=62) found brain networks reorganized into different patterns depending on setting (rest, music, etc.), with more reorganization predicting more next-day benefit. Another study found increased brain entropy and white-matter density one month after a dose, with insight mediating well-being gains. However, negative findings are accumulating for microdosing: a new preclinical study in rats found chronic psilocin microdosing produced limited behavioral effects and no enhanced neurogenesis, and a review argues the strongest studies show limited benefits. A Phase 1 study identified 2.5 mg as the threshold for a perceptible dose in healthy adults.

Other early-stage signals include a pilot RCT finding psilocybin reduced egocentric bias in alcohol use disorder, a protocol for combining apomorphine and psilocybin for coma recovery, and exploratory studies in methamphetamine use disorder. On the product side, Cybin Inc. has changed its legal name to Helus Pharma, which is developing a deuterated psilocybin analog (HLP003) in Phase 3 for MDD. Filament Health’s natural psilocybin extract (PEX010) is being supplied for trials in palliative care.

Written 2026-10-03 from the changelog below, not from a fresh search.

How the field breaks down, by what we're actually tracking:

• other-psychiatric — 5 items: OCD, PTSD, Chronic suicidal ideation, Methamphetamine use disorder, Alcohol use disorder.
• depression — 3 items: Treatment-resistant depression, Major depressive disorder, Bipolar II depression.
• medical — 3 items: Post-treatment Lyme disease, Chemo nerve damage, Coma / Disorders of consciousness.
• pharmaceutical — 2 items: PEX010 (Filament Health), HLP003 (Helus Pharma).
• regulatory — 1 item: Real-world use (state programs).
• mechanism — 1 item: Mechanism.

Tracked products

Available now. Price and regulatory status are blank where we have not read them on a primary source — they are never inferred.

Upcoming

Announced, no date.

Major depressive disorder

Usona Institute's Phase 3 completed enrolment; it holds an FDA priority voucher. No readout as of 2026-10-02.

First seen 2026-10-02 · confidence secondary · depression

Why it's here: RCT, n=37: Single moderate dose of psilocybin (0.215 mg/kg) significantly reduced depressive symptoms and improved self-concept in MDD. (2026-10-03) — A randomized, double-blind, placebo-controlled trial found psilocybin superior to placebo on the BDI, MADRS, and self-concept measures.

Sources: WPR

HLP003 (Helus Pharma)

Deuterated psilocybin analog in Phase 3 clinical development for adjunctive treatment of major depressive disorder.

First seen 2026-10-03 · confidence unverified · pharmaceutical

Why it's here: No changelog entry explains this status yet.

Sources: Yahoo Finance

Coming Soon

Announced with a date, or an open pre-order.

Nothing in this bucket right now.

What We're Watching

Exists, unproven, or newly discovered. This is where auto-discovered items land.

Chemo nerve damage

Preclinical (mice): preventive psilocybin blocked cisplatin/paclitaxel neuropathy. NeuroGuard Phase 2 (n=83) slated to start 2026-11-04.

First seen 2026-10-02 · confidence primary-source · medical

Why it's here: Mice: two preventive doses blocked cisplatin/paclitaxel nerve damage for 8 months without blunting chemo; non-hallucinogenic tabernanthalog worked as well. (2026-10-02) — MD Anderson, Science. Mechanism: TrkB-Akt-PAK5 signalling keeps mitochondria moving along axons. Protective only; did not reverse existing damage. NeuroGuard Phase 2 (NCT07227909, n=83) slated to start 2026-11-04.

Sources: NeuroGuard (NCT07227909)

Mechanism

Brain entropy, network reorganisation shaped by setting, insight as the mediator of benefit, and a non-hallucinogenic analogue that matched psilocybin in one preclinical model.

First seen 2026-10-02 · confidence primary-source · mechanism

Why it's here: Protocol: Open-label dose-escalation study of apomorphine + psilocybin for recovery from coma in ICU. (2026-10-03) — A prospective, open-label, bicentric, phase 1b study enrolling 80 ICU patients with disorders of consciousness to test safety and potential efficacy of combining apomorphine (arousal) with psilocybin (awareness).

Sources: none recorded — this item is a name we've seen and not much more.

PEX010 (Filament Health)

A natural psilocybin extract being supplied for clinical trials in palliative care and other indications.

First seen 2026-10-03 · confidence unverified · pharmaceutical

Why it's here: No changelog entry explains this status yet.

Sources: Yahoo Finance article referencing supply

Methamphetamine use disorder

Exploratory study of psilocybin administration for functional connectivity changes in individuals with methamphetamine use disorder.

First seen 2026-10-03 · confidence unverified · other-psychiatric

Why it's here: No changelog entry explains this status yet.

Sources: AJNR

Alcohol use disorder

Pilot RCT investigating psilocybin's effect on egocentric bias in individuals with alcohol use disorder.

First seen 2026-10-03 · confidence unverified · other-psychiatric

Why it's here: No changelog entry explains this status yet.

Sources: preprint

Coma / Disorders of consciousness

Phase 1b study protocol testing apomorphine and psilocybin for recovery of consciousness in ICU patients with brain injury.

First seen 2026-10-03 · confidence unverified · medical

Why it's here: No changelog entry explains this status yet.

Sources: BMJ Open

Promising

Early-stage, but the evidence or the approach is genuinely interesting. The only editorial bucket on this page — an item only lands here with a reason recorded in the changelog.

Treatment-resistant depression

The most mature indication: two positive Compass Phase 3 trials, a positive NHS RCT, and one German Phase 2b that missed its primary.

First seen 2026-10-02 · confidence primary-source · depression

Why it's here: Compass Pathways' 52-week open-label data from Phase 3 COMP005 shows additional benefit from another COMP360 dose, extending durability out to 1 year. (2026-10-03) — Compass Pathways announced topline 52-week results from the Part C open-label extension of its Phase 3 COMP005 trial, demonstrating an additional benefit from a third COMP360 dose and supporting the potential for long-lasting benefit.

Sources: Compass FDA announcement

Bipolar II depression

One open-label dose-escalation pilot (n=14). Large MADRS drops; 3 of 14 had transient suicidal ideation or hypomania.

First seen 2026-10-02 · confidence primary-source · depression

Why it's here: Case report: Psilocybin worsened depression and anxiety in a patient with cyclothymia. (2026-10-03) — A case report published in The Journal of Clinical Psychiatry details worsening of depression and anxiety symptoms following psilocybin use in a patient with cyclothymia, suggesting potential risk in those with underlying mood instability.

Sources: none recorded — this item is a name we've seen and not much more.

OCD

One small randomized trial (n=15) of up to eight doses; 73% responders at 8 weeks.

First seen 2026-10-02 · confidence primary-source · other-psychiatric

Why it's here: Preclinical study: Single psilocybin dose improves social behavior in OCD mouse model. (2026-10-03) — A study in SAPAP3 knockout mice found psilocybin restored social novelty exploration, with effects linked to infralimbic prefrontal cortex activation.

Sources: none recorded — this item is a name we've seen and not much more.

PTSD

One open-label pilot in veterans with severe treatment-resistant PTSD (n=12); 9 of 12 in remission at one month.

First seen 2026-10-02 · confidence primary-source · other-psychiatric

Why it's here: Open-label, n=12 veterans with severe treatment-resistant PTSD, 15 + 25 mg: clinician-rated PTSD score -27.5 at 1 month; 9 of 12 in remission. (2026-10-02) — Ohio State, Communications Medicine. No serious adverse events; suicidal ideation unchanged. 6-month follow-up planned.

Sources: none recorded — this item is a name we've seen and not much more.

Chronic suicidal ideation

One open-label trial (n=20) at Sheppard Pratt; ~70% had little or no suicidal ideation at 12 weeks.

First seen 2026-10-02 · confidence secondary · other-psychiatric

Why it's here: Open-label, n=20: ~70% had little or no suicidal ideation 12 weeks after psilocybin with therapy. (2026-10-02) — Sheppard Pratt trial in chronic suicidal ideation. Reported via the Baltimore Sun; the paper itself was not located at seeding, so dose and scale details are unconfirmed.

Sources: none recorded — this item is a name we've seen and not much more.

Post-treatment Lyme disease

One Johns Hopkins open-label pilot (n=20); symptom burden down ~40%, sustained to 6 months.

First seen 2026-10-02 · confidence primary-source · medical

Why it's here: Open-label, n=20, two doses: symptom burden -40% and quality of life +13%, sustained to 6 months. (2026-10-02) — Johns Hopkins (Garcia-Romeu), Scientific Reports. Fatigue, depression, pain and sleep also improved. All 20 completed. Transient hypertension in 90%, headache 65%.

Sources: none recorded — this item is a name we've seen and not much more.

Open questions

Publishing what we don't know is the point. These are things the job is actively watching for; when one gets answered it becomes a changelog entry and moves down here to the answered list.

• Has the FDA approved COMP360 for treatment-resistant depression, and has the DEA rescheduled psilocybin? — open since 2026-10-02.
• What did Usona Institute's Phase 3 in major depressive disorder find? — open since 2026-10-02.
• Is the subjective experience necessary for the therapeutic effect in humans? Any head-to-head of psilocybin vs a non-hallucinogenic analogue? — open since 2026-10-02.
• Has any trial convincingly solved blinding (active placebo, naive raters, expectancy measurement) and what did the effect size become? — open since 2026-10-02.
• What is the durability of benefit beyond 6 months, and how often is re-dosing needed? — open since 2026-10-02.

Full changelog

Everything, newest first, grouped by the month we found it. Long by design — it's the receipts.

October 2026

Dreamlab Live Research uses autonomous systems to track the state of the art in fields of interest. New trackers appear as the interests do.

Generated from a versioned dataset in a git repository: every state this page has ever been in is a commit, and a bad run is revertible. The dataset is the source; this page is build output and is not itself edited.

• Dataset: data/live-research/psilocybin.json (schema version 2)
• Runs completed: 2 · cadence: daily
• Items tracked: 15 · changelog entries: 26
• Distinct sources seen: 162
• Last run recorded: 2026-10-03T06:10:39Z (status: ok)